English
简体中文
Total: £ 56.28
Published Date: 2026-01-22 | Pages: 119 | Tables: 113 | Medical Care
The global New Chemical Entities (NCE) CDMO market was valued at US$ 3242 million in 2025 and is anticipated to reach US$ 6811 million by 2032, at a CAGR of 11.4% from 2026 to 2032.
New Chemical Entities (NCE) refer to new compounds that have not yet been approved for any therapeutic use during the drug development process. These compounds are usually obtained through the synthesis or discovery of new molecules and have new activities or therapeutic potential. NCE is usually the first step in drug development, and after evaluating its safety and effectiveness in clinical trials, it may be applied for marketing. CDMO (Contract Development and Manufacturing Organization) refers to a company that provides drug development and production services, usually working with pharmaceutical companies to help them develop and manufacture NCE. CDMO can provide a range of services from preliminary compound synthesis, process development, to the production of drugs for clinical trials and commercial production. In short, NCE is a newly developed drug ingredient, and CDMO is a service provider that specializes in helping pharmaceutical companies develop and produce NCE.
The North American market for New Chemical Entities (NCE) CDMO is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for New Chemical Entities (NCE) CDMO is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for New Chemical Entities (NCE) CDMO in Tumors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of New Chemical Entities (NCE) CDMO include KATSURA CHEMICAL CO., LTD, Regis Custom API, Neuland Laboratories Ltd., Aspen API, Sai Life Sciences, Fermion, Dipharma Francis Srl (Dipharma), Cohance, Suven Pharma, Syngene, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global New Chemical Entities (NCE) CDMO market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding New Chemical Entities (NCE) CDMO. The New Chemical Entities (NCE) CDMO market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global New Chemical Entities (NCE) CDMO market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist New Chemical Entities (NCE) CDMO manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
KATSURA CHEMICAL CO., LTD
Regis Custom API
Neuland Laboratories Ltd.
Aspen API
Sai Life Sciences
Fermion
Dipharma Francis Srl (Dipharma)
Cohance
Suven Pharma
Syngene
Aarti Pharmalabs Limited (APL)
Cerbios-Pharma SA
PharmaBlock Sciences Nanjing Inc
Segment by Type
Peptide NCE
Oligonucleotide NCE
Other
Segment by Application
Tumors
Cardiovascular Diseases
Other
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for New Chemical Entities (NCE) CDMO companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global New Chemical Entities (NCE) CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Peptide NCE
1.2.3 Oligonucleotide NCE
1.2.4 Other
1.3 Market by Application
1.3.1 Global New Chemical Entities (NCE) CDMO Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Tumors
1.3.3 Cardiovascular Diseases
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global New Chemical Entities (NCE) CDMO Market Perspective (2021–2032)
2.2 Global New Chemical Entities (NCE) CDMO Growth Trends by Region
2.2.1 Global New Chemical Entities (NCE) CDMO Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 New Chemical Entities (NCE) CDMO Historic Market Size by Region (2021–2026)
2.2.3 New Chemical Entities (NCE) CDMO Forecasted Market Size by Region (2027–2032)
2.3 New Chemical Entities (NCE) CDMO Market Dynamics
2.3.1 New Chemical Entities (NCE) CDMO Industry Trends
2.3.2 New Chemical Entities (NCE) CDMO Market Drivers
2.3.3 New Chemical Entities (NCE) CDMO Market Challenges
2.3.4 New Chemical Entities (NCE) CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top New Chemical Entities (NCE) CDMO Players by Revenue
3.1.1 Global Top New Chemical Entities (NCE) CDMO Players by Revenue (2021–2026)
3.1.2 Global New Chemical Entities (NCE) CDMO Revenue Market Share by Players (2021–2026)
3.2 Global Top New Chemical Entities (NCE) CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by New Chemical Entities (NCE) CDMO Revenue
3.4 Global New Chemical Entities (NCE) CDMO Market Concentration Ratio
3.4.1 Global New Chemical Entities (NCE) CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by New Chemical Entities (NCE) CDMO Revenue in 2025
3.5 Global Key Players of New Chemical Entities (NCE) CDMO Head Offices and Areas Served
3.6 Global Key Players of New Chemical Entities (NCE) CDMO, Products and Applications
3.7 Global Key Players of New Chemical Entities (NCE) CDMO, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 New Chemical Entities (NCE) CDMO Breakdown Data by Type
4.1 Global New Chemical Entities (NCE) CDMO Historic Market Size by Type (2021–2026)
4.2 Global New Chemical Entities (NCE) CDMO Forecasted Market Size by Type (2027–2032)
5 New Chemical Entities (NCE) CDMO Breakdown Data by Application
5.1 Global New Chemical Entities (NCE) CDMO Historic Market Size by Application (2021–2026)
5.2 Global New Chemical Entities (NCE) CDMO Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America New Chemical Entities (NCE) CDMO Market Size (2021–2032)
6.2 North America New Chemical Entities (NCE) CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America New Chemical Entities (NCE) CDMO Market Size by Country (2021–2026)
6.4 North America New Chemical Entities (NCE) CDMO Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe New Chemical Entities (NCE) CDMO Market Size (2021–2032)
7.2 Europe New Chemical Entities (NCE) CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe New Chemical Entities (NCE) CDMO Market Size by Country (2021–2026)
7.4 Europe New Chemical Entities (NCE) CDMO Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific New Chemical Entities (NCE) CDMO Market Size (2021–2032)
8.2 Asia-Pacific New Chemical Entities (NCE) CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific New Chemical Entities (NCE) CDMO Market Size by Region (2021–2026)
8.4 Asia-Pacific New Chemical Entities (NCE) CDMO Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America New Chemical Entities (NCE) CDMO Market Size (2021–2032)
9.2 Latin America New Chemical Entities (NCE) CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America New Chemical Entities (NCE) CDMO Market Size by Country (2021–2026)
9.4 Latin America New Chemical Entities (NCE) CDMO Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa New Chemical Entities (NCE) CDMO Market Size (2021–2032)
10.2 Middle East & Africa New Chemical Entities (NCE) CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa New Chemical Entities (NCE) CDMO Market Size by Country (2021–2026)
10.4 Middle East & Africa New Chemical Entities (NCE) CDMO Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 KATSURA CHEMICAL CO., LTD
11.1.1 KATSURA CHEMICAL CO., LTD Company Details
11.1.2 KATSURA CHEMICAL CO., LTD Business Overview
11.1.3 KATSURA CHEMICAL CO., LTD New Chemical Entities (NCE) CDMO Introduction
11.1.4 KATSURA CHEMICAL CO., LTD Revenue in New Chemical Entities (NCE) CDMO Business (2021–2026)
11.1.5 KATSURA CHEMICAL CO., LTD Recent Development
11.2 Regis Custom API
11.2.1 Regis Custom API Company Details
11.2.2 Regis Custom API Business Overview
11.2.3 Regis Custom API New Chemical Entities (NCE) CDMO Introduction
11.2.4 Regis Custom API Revenue in New Chemical Entities (NCE) CDMO Business (2021–2026)
11.2.5 Regis Custom API Recent Development
11.3 Neuland Laboratories Ltd.
11.3.1 Neuland Laboratories Ltd. Company Details
11.3.2 Neuland Laboratories Ltd. Business Overview
11.3.3 Neuland Laboratories Ltd. New Chemical Entities (NCE) CDMO Introduction
11.3.4 Neuland Laboratories Ltd. Revenue in New Chemical Entities (NCE) CDMO Business (2021–2026)
11.3.5 Neuland Laboratories Ltd. Recent Development
11.4 Aspen API
11.4.1 Aspen API Company Details
11.4.2 Aspen API Business Overview
11.4.3 Aspen API New Chemical Entities (NCE) CDMO Introduction
11.4.4 Aspen API Revenue in New Chemical Entities (NCE) CDMO Business (2021–2026)
11.4.5 Aspen API Recent Development
11.5 Sai Life Sciences
11.5.1 Sai Life Sciences Company Details
11.5.2 Sai Life Sciences Business Overview
11.5.3 Sai Life Sciences New Chemical Entities (NCE) CDMO Introduction
11.5.4 Sai Life Sciences Revenue in New Chemical Entities (NCE) CDMO Business (2021–2026)
11.5.5 Sai Life Sciences Recent Development
11.6 Fermion
11.6.1 Fermion Company Details
11.6.2 Fermion Business Overview
11.6.3 Fermion New Chemical Entities (NCE) CDMO Introduction
11.6.4 Fermion Revenue in New Chemical Entities (NCE) CDMO Business (2021–2026)
11.6.5 Fermion Recent Development
11.7 Dipharma Francis Srl (Dipharma)
11.7.1 Dipharma Francis Srl (Dipharma) Company Details
11.7.2 Dipharma Francis Srl (Dipharma) Business Overview
11.7.3 Dipharma Francis Srl (Dipharma) New Chemical Entities (NCE) CDMO Introduction
11.7.4 Dipharma Francis Srl (Dipharma) Revenue in New Chemical Entities (NCE) CDMO Business (2021–2026)
11.7.5 Dipharma Francis Srl (Dipharma) Recent Development
11.8 Cohance
11.8.1 Cohance Company Details
11.8.2 Cohance Business Overview
11.8.3 Cohance New Chemical Entities (NCE) CDMO Introduction
11.8.4 Cohance Revenue in New Chemical Entities (NCE) CDMO Business (2021–2026)
11.8.5 Cohance Recent Development
11.9 Suven Pharma
11.9.1 Suven Pharma Company Details
11.9.2 Suven Pharma Business Overview
11.9.3 Suven Pharma New Chemical Entities (NCE) CDMO Introduction
11.9.4 Suven Pharma Revenue in New Chemical Entities (NCE) CDMO Business (2021–2026)
11.9.5 Suven Pharma Recent Development
11.10 Syngene
11.10.1 Syngene Company Details
11.10.2 Syngene Business Overview
11.10.3 Syngene New Chemical Entities (NCE) CDMO Introduction
11.10.4 Syngene Revenue in New Chemical Entities (NCE) CDMO Business (2021–2026)
11.10.5 Syngene Recent Development
11.11 Aarti Pharmalabs Limited (APL)
11.11.1 Aarti Pharmalabs Limited (APL) Company Details
11.11.2 Aarti Pharmalabs Limited (APL) Business Overview
11.11.3 Aarti Pharmalabs Limited (APL) New Chemical Entities (NCE) CDMO Introduction
11.11.4 Aarti Pharmalabs Limited (APL) Revenue in New Chemical Entities (NCE) CDMO Business (2021–2026)
11.11.5 Aarti Pharmalabs Limited (APL) Recent Development
11.12 Cerbios-Pharma SA
11.12.1 Cerbios-Pharma SA Company Details
11.12.2 Cerbios-Pharma SA Business Overview
11.12.3 Cerbios-Pharma SA New Chemical Entities (NCE) CDMO Introduction
11.12.4 Cerbios-Pharma SA Revenue in New Chemical Entities (NCE) CDMO Business (2021–2026)
11.12.5 Cerbios-Pharma SA Recent Development
11.13 PharmaBlock Sciences Nanjing Inc
11.13.1 PharmaBlock Sciences Nanjing Inc Company Details
11.13.2 PharmaBlock Sciences Nanjing Inc Business Overview
11.13.3 PharmaBlock Sciences Nanjing Inc New Chemical Entities (NCE) CDMO Introduction
11.13.4 PharmaBlock Sciences Nanjing Inc Revenue in New Chemical Entities (NCE) CDMO Business (2021–2026)
11.13.5 PharmaBlock Sciences Nanjing Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global New Chemical Entities (NCE) CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Peptide NCE
Table 3. Key Players of Oligonucleotide NCE
Table 4. Key Players of Other
Table 5. Global New Chemical Entities (NCE) CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global New Chemical Entities (NCE) CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global New Chemical Entities (NCE) CDMO Market Size by Region (US$ Million), 2021–2026
Table 8. Global New Chemical Entities (NCE) CDMO Market Share by Region (2021–2026)
Table 9. Global New Chemical Entities (NCE) CDMO Forecasted Market Size by Region (US$ Million), 2027–2032
Table 10. Global New Chemical Entities (NCE) CDMO Market Share by Region (2027–2032)
Table 11. New Chemical Entities (NCE) CDMO Market Trends
Table 12. New Chemical Entities (NCE) CDMO Market Drivers
Table 13. New Chemical Entities (NCE) CDMO Market Challenges
Table 14. New Chemical Entities (NCE) CDMO Market Restraints
Table 15. Global New Chemical Entities (NCE) CDMO Revenue by Players (US$ Million), 2021–2026
Table 16. Global New Chemical Entities (NCE) CDMO Market Share by Players (2021–2026)
Table 17. Global Top New Chemical Entities (NCE) CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on New Chemical Entities (NCE) CDMO Revenue, 2025
Table 18. Ranking of Global Top New Chemical Entities (NCE) CDMO Companies by Revenue (US$ Million) in 2025
Table 19. Global 5 Largest Players Market Share by New Chemical Entities (NCE) CDMO Revenue (CR5 and HHI), 2021–2026
Table 20. Global Key Players of New Chemical Entities (NCE) CDMO, Headquarters and Area Served
Table 21. Global Key Players of New Chemical Entities (NCE) CDMO, Products and Applications
Table 22. Global Key Players of New Chemical Entities (NCE) CDMO, Date of General Availability (GA)
Table 23. Mergers and Acquisitions, Expansion Plans
Table 24. Global New Chemical Entities (NCE) CDMO Market Size by Type (US$ Million), 2021–2026
Table 25. Global New Chemical Entities (NCE) CDMO Revenue Market Share by Type (2021–2026)
Table 26. Global New Chemical Entities (NCE) CDMO Forecasted Market Size by Type (US$ Million), 2027–2032
Table 27. Global New Chemical Entities (NCE) CDMO Revenue Market Share by Type (2027–2032)
Table 28. Global New Chemical Entities (NCE) CDMO Market Size by Application (US$ Million), 2021–2026
Table 29. Global New Chemical Entities (NCE) CDMO Revenue Market Share by Application (2021–2026)
Table 30. Global New Chemical Entities (NCE) CDMO Forecasted Market Size by Application (US$ Million), 2027–2032
Table 31. Global New Chemical Entities (NCE) CDMO Revenue Market Share by Application (2027–2032)
Table 32. North America New Chemical Entities (NCE) CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 33. North America New Chemical Entities (NCE) CDMO Market Size by Country (US$ Million), 2021–2026
Table 34. North America New Chemical Entities (NCE) CDMO Market Size by Country (US$ Million), 2027–2032
Table 35. Europe New Chemical Entities (NCE) CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 36. Europe New Chemical Entities (NCE) CDMO Market Size by Country (US$ Million), 2021–2026
Table 37. Europe New Chemical Entities (NCE) CDMO Market Size by Country (US$ Million), 2027–2032
Table 38. Asia-Pacific New Chemical Entities (NCE) CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 39. Asia-Pacific New Chemical Entities (NCE) CDMO Market Size by Region (US$ Million), 2021–2026
Table 40. Asia-Pacific New Chemical Entities (NCE) CDMO Market Size by Region (US$ Million), 2027–2032
Table 41. Latin America New Chemical Entities (NCE) CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 42. Latin America New Chemical Entities (NCE) CDMO Market Size by Country (US$ Million), 2021–2026
Table 43. Latin America New Chemical Entities (NCE) CDMO Market Size by Country (US$ Million), 2027–2032
Table 44. Middle East & Africa New Chemical Entities (NCE) CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 45. Middle East & Africa New Chemical Entities (NCE) CDMO Market Size by Country (US$ Million), 2021–2026
Table 46. Middle East & Africa New Chemical Entities (NCE) CDMO Market Size by Country (US$ Million), 2027–2032
Table 47. KATSURA CHEMICAL CO., LTD Company Details
Table 48. KATSURA CHEMICAL CO., LTD Business Overview
Table 49. KATSURA CHEMICAL CO., LTD New Chemical Entities (NCE) CDMO Product
Table 50. KATSURA CHEMICAL CO., LTD Revenue in New Chemical Entities (NCE) CDMO Business (US$ Million), 2021–2026
Table 51. KATSURA CHEMICAL CO., LTD Recent Development
Table 52. Regis Custom API Company Details
Table 53. Regis Custom API Business Overview
Table 54. Regis Custom API New Chemical Entities (NCE) CDMO Product
Table 55. Regis Custom API Revenue in New Chemical Entities (NCE) CDMO Business (US$ Million), 2021–2026
Table 56. Regis Custom API Recent Development
Table 57. Neuland Laboratories Ltd. Company Details
Table 58. Neuland Laboratories Ltd. Business Overview
Table 59. Neuland Laboratories Ltd. New Chemical Entities (NCE) CDMO Product
Table 60. Neuland Laboratories Ltd. Revenue in New Chemical Entities (NCE) CDMO Business (US$ Million), 2021–2026
Table 61. Neuland Laboratories Ltd. Recent Development
Table 62. Aspen API Company Details
Table 63. Aspen API Business Overview
Table 64. Aspen API New Chemical Entities (NCE) CDMO Product
Table 65. Aspen API Revenue in New Chemical Entities (NCE) CDMO Business (US$ Million), 2021–2026
Table 66. Aspen API Recent Development
Table 67. Sai Life Sciences Company Details
Table 68. Sai Life Sciences Business Overview
Table 69. Sai Life Sciences New Chemical Entities (NCE) CDMO Product
Table 70. Sai Life Sciences Revenue in New Chemical Entities (NCE) CDMO Business (US$ Million), 2021–2026
Table 71. Sai Life Sciences Recent Development
Table 72. Fermion Company Details
Table 73. Fermion Business Overview
Table 74. Fermion New Chemical Entities (NCE) CDMO Product
Table 75. Fermion Revenue in New Chemical Entities (NCE) CDMO Business (US$ Million), 2021–2026
Table 76. Fermion Recent Development
Table 77. Dipharma Francis Srl (Dipharma) Company Details
Table 78. Dipharma Francis Srl (Dipharma) Business Overview
Table 79. Dipharma Francis Srl (Dipharma) New Chemical Entities (NCE) CDMO Product
Table 80. Dipharma Francis Srl (Dipharma) Revenue in New Chemical Entities (NCE) CDMO Business (US$ Million), 2021–2026
Table 81. Dipharma Francis Srl (Dipharma) Recent Development
Table 82. Cohance Company Details
Table 83. Cohance Business Overview
Table 84. Cohance New Chemical Entities (NCE) CDMO Product
Table 85. Cohance Revenue in New Chemical Entities (NCE) CDMO Business (US$ Million), 2021–2026
Table 86. Cohance Recent Development
Table 87. Suven Pharma Company Details
Table 88. Suven Pharma Business Overview
Table 89. Suven Pharma New Chemical Entities (NCE) CDMO Product
Table 90. Suven Pharma Revenue in New Chemical Entities (NCE) CDMO Business (US$ Million), 2021–2026
Table 91. Suven Pharma Recent Development
Table 92. Syngene Company Details
Table 93. Syngene Business Overview
Table 94. Syngene New Chemical Entities (NCE) CDMO Product
Table 95. Syngene Revenue in New Chemical Entities (NCE) CDMO Business (US$ Million), 2021–2026
Table 96. Syngene Recent Development
Table 97. Aarti Pharmalabs Limited (APL) Company Details
Table 98. Aarti Pharmalabs Limited (APL) Business Overview
Table 99. Aarti Pharmalabs Limited (APL) New Chemical Entities (NCE) CDMO Product
Table 100. Aarti Pharmalabs Limited (APL) Revenue in New Chemical Entities (NCE) CDMO Business (US$ Million), 2021–2026
Table 101. Aarti Pharmalabs Limited (APL) Recent Development
Table 102. Cerbios-Pharma SA Company Details
Table 103. Cerbios-Pharma SA Business Overview
Table 104. Cerbios-Pharma SA New Chemical Entities (NCE) CDMO Product
Table 105. Cerbios-Pharma SA Revenue in New Chemical Entities (NCE) CDMO Business (US$ Million), 2021–2026
Table 106. Cerbios-Pharma SA Recent Development
Table 107. PharmaBlock Sciences Nanjing Inc Company Details
Table 108. PharmaBlock Sciences Nanjing Inc Business Overview
Table 109. PharmaBlock Sciences Nanjing Inc New Chemical Entities (NCE) CDMO Product
Table 110. PharmaBlock Sciences Nanjing Inc Revenue in New Chemical Entities (NCE) CDMO Business (US$ Million), 2021–2026
Table 111. PharmaBlock Sciences Nanjing Inc Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
Table 115. Authors List of This Report
List of Figures
Figure 1. New Chemical Entities (NCE) CDMO Picture
Figure 2. Global New Chemical Entities (NCE) CDMO Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global New Chemical Entities (NCE) CDMO Market Share by Type: 2025 vs 2032
Figure 4. Peptide NCE Features
Figure 5. Oligonucleotide NCE Features
Figure 6. Other Features
Figure 7. Global New Chemical Entities (NCE) CDMO Market Size by Application (US$ Million), 2021–2032
Figure 8. Global New Chemical Entities (NCE) CDMO Market Share by Application: 2025 vs 2032
Figure 9. Tumors Case Studies
Figure 10. Cardiovascular Diseases Case Studies
Figure 11. Other Case Studies
Figure 12. New Chemical Entities (NCE) CDMO Report Years Considered
Figure 13. Global New Chemical Entities (NCE) CDMO Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 14. Global New Chemical Entities (NCE) CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global New Chemical Entities (NCE) CDMO Market Share by Region: 2025 vs 2032
Figure 16. Global New Chemical Entities (NCE) CDMO Market Share by Players in 2025
Figure 17. Global New Chemical Entities (NCE) CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by New Chemical Entities (NCE) CDMO Revenue in 2025
Figure 19. North America New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 20. North America New Chemical Entities (NCE) CDMO Market Share by Country (2021–2032)
Figure 21. United States New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Canada New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Europe New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe New Chemical Entities (NCE) CDMO Market Share by Country (2021–2032)
Figure 25. Germany New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. France New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. U.K. New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Italy New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Russia New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Ireland New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Asia-Pacific New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific New Chemical Entities (NCE) CDMO Market Share by Region (2021–2032)
Figure 33. China New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Japan New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. South Korea New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Southeast Asia New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. India New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Australia & New Zealand New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Latin America New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America New Chemical Entities (NCE) CDMO Market Share by Country (2021–2032)
Figure 41. Mexico New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Brazil New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Middle East & Africa New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa New Chemical Entities (NCE) CDMO Market Share by Country (2021–2032)
Figure 45. Israel New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Saudi Arabia New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. UAE New Chemical Entities (NCE) CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. KATSURA CHEMICAL CO., LTD Revenue Growth Rate in New Chemical Entities (NCE) CDMO Business (2021–2026)
Figure 49. Regis Custom API Revenue Growth Rate in New Chemical Entities (NCE) CDMO Business (2021–2026)
Figure 50. Neuland Laboratories Ltd. Revenue Growth Rate in New Chemical Entities (NCE) CDMO Business (2021–2026)
Figure 51. Aspen API Revenue Growth Rate in New Chemical Entities (NCE) CDMO Business (2021–2026)
Figure 52. Sai Life Sciences Revenue Growth Rate in New Chemical Entities (NCE) CDMO Business (2021–2026)
Figure 53. Fermion Revenue Growth Rate in New Chemical Entities (NCE) CDMO Business (2021–2026)
Figure 54. Dipharma Francis Srl (Dipharma) Revenue Growth Rate in New Chemical Entities (NCE) CDMO Business (2021–2026)
Figure 55. Cohance Revenue Growth Rate in New Chemical Entities (NCE) CDMO Business (2021–2026)
Figure 56. Suven Pharma Revenue Growth Rate in New Chemical Entities (NCE) CDMO Business (2021–2026)
Figure 57. Syngene Revenue Growth Rate in New Chemical Entities (NCE) CDMO Business (2021–2026)
Figure 58. Aarti Pharmalabs Limited (APL) Revenue Growth Rate in New Chemical Entities (NCE) CDMO Business (2021–2026)
Figure 59. Cerbios-Pharma SA Revenue Growth Rate in New Chemical Entities (NCE) CDMO Business (2021–2026)
Figure 60. PharmaBlock Sciences Nanjing Inc Revenue Growth Rate in New Chemical Entities (NCE) CDMO Business (2021–2026)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
